Possible role of goserelin, an LH-RH agonist in the treatment of gynaecological cancers.
Twenty-one patients were enrolled in a pilot study in order to evaluate the clinical efficacy of the GnRH analogues in the treatment of hormone dependent gynaecological malignancies. Seven patients with recurrent or advanced endometrial adenocarcinoma and fourteen patients with ovarian carcinoma had a 4-weekly subcutaneous injection in the abdominal wall of 3.6 mg goserelin (Zoladex--ICI Pharmaceuticals). Overall, four of the 21 patients showed regression, nine had their disease stabilised and eight showed progression. No important side effects were noticed.